{"id":"W4387810347","doi":"10.1016/j.annonc.2023.09.2728","title":"1778P Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"CancerCare Manitoba; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Clinical endpoint; Urology; Placebo; Internal medicine; Gynecology; Oncology; Gastroenterology; Randomized controlled trial; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002578122,0.001118545,0.001962728,0.0006899021,0.0004310788,0.001014192,0.0005815227,0.0007316902,0.007121979],"category_scores_gemma":[0.001348148,0.0002297642,0.002346129,0.0007407163,0.0004070565,0.0009272348,0.0006045607,0.002475071,0.001195226],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001102506,"about_ca_system_score_gemma":0.00177087,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0017605,"about_ca_topic_score_gemma":0.005125869,"domain_scores_codex":[0.9990011,0.0004917977,0.0000759203,0.0001178793,0.0001603203,0.0001529694],"domain_scores_gemma":[0.9989261,0.0002778027,0.0002667517,0.00008525228,0.000136769,0.0003072853],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8038793,0.00778279,0.01918923,0.004713312,0.008696284,0.0002254855,0.000110981,0.002997996,0.008298947,0.0004941415,0.0126561,0.1309555],"study_design_scores_gemma":[0.2838618,0.429713,0.1963267,0.001184694,0.01660582,0.001126354,0.0003721348,0.003135028,0.01792047,0.002226574,0.04733958,0.0001878599],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9391461,0.01276671,0.001119985,0.000789553,0.000329256,0.003172004,0.02282136,0.0002047001,0.01965036],"genre_scores_gemma":[0.9541773,0.005207316,0.001437979,0.001074653,0.0003734828,0.003581732,0.02563148,0.000067748,0.008448323],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007121979,"threshold_uncertainty_score":0.02382541,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04619213243928624,"score_gpt":0.3734757764249406,"score_spread":0.3272836439856543,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}